Trials / Completed
CompletedNCT01178099
An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults
A Pharmacokinetic and Pharmacodynamic Assessment of Prasugrel in Healthy Adults and Adults With Sickle Cell Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to measure the exposure to prasugrel's active metabolite and the pharmacodynamic effects of prasugrel treatment in people with Sickle Cell Disease (SCD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prasugrel | Oral, daily for 12 days |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2010-08-09
- Last updated
- 2012-02-15
- Results posted
- 2012-02-15
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01178099. Inclusion in this directory is not an endorsement.